Generation Bio Inc. (GBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBIO Stock Price Chart Interactive Chart >
GBIO Price/Volume Stats
|Current price||$27.00||52-week high||$55.72|
|Prev. close||$27.31||52-week low||$17.00|
|Day high||$27.55||Avg. volume||571,187|
|50-day MA||$30.88||Dividend yield||N/A|
|200-day MA||$31.40||Market Cap||1.53B|
Generation Bio Inc. (GBIO) Company Bio
Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
GBIO Latest News Stream
|Loading, please wait...|
GBIO Latest Social Stream
View Full GBIO Social Stream
Latest GBIO News From Around the Web
Below are the latest news stories about Generation Bio Co that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 16, at 11:30 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A repla
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform Potent factor VIII construct optimized by taking advantage of the increased cargo capacity of closed-ended DNA CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported data from multiple digital presentations during the ongoing 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting as well as first quarter 2021 financial results. “We are excited to highlight two significant new developments for...
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:00 p.m. ET. A live webcast of the fireside chat will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rar...
Generation Bio Is it time to Buy before this week’s earning report Stock market Insights & financial analysis
Generation Bio announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GBIO Price Returns